21 results on '"OVERALL survival"'
Search Results
2. Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC.
3. New Data Augment the Treatment Paradigm in HR+/HER2- Breast Cancer.
4. Adding Chemotherapy to Frontline Osimertinib Is Under Debate in EGFR-Mutated NSCLC..
5. Perioperative Pembrolizumab/ Chemo Regimen Yields Superior OS in Resectable Gastric Cancer.
6. 18-Month Survival Results of Neoadjuvant Cemiplimab in Advanced Resectable CSCC May Lead to Reconsideration of Adjuvant Treatment.
7. Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC.
8. Blinatumomab Receives Approval for CD19+ B-ALL in the Consolidation Phase.
9. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.
10. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.
11. Clinical Updates: PROSTATE CANCER. Survival may be improving in de novo mHSPC, new data suggest.
12. Clinical Updates: BLADDER CANCER. Adding durvalumab to chemotherapy extends survival in MIBC.
13. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.
14. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.
15. Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer.
16. Blue light cystoscopy decreases risk of recurrence, progression in NMIBC.
17. Prostate cancer treatment deintensification: When less is more.
18. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.
19. Diagnosis of Second Primary Malignancies Is Associated With Prolonged Survival Among Patients With MM.
20. Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.
21. Hypertension predicts worse outcomes for patients undergoing nephroureterectomy for UTUC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.